Waly Dioh - Biophytis Chief Officer
| BPTSDelisted Stock | USD 7.03 0.00 0.00% |
Insider
Waly Dioh is Chief Officer of Biophytis
| Age | 55 |
| Phone | 33 1 44 27 23 00 |
| Web | https://www.biophytis.com |
Biophytis Management Efficiency
The company has return on total asset (ROA) of (0.5278) % which means that it has lost $0.5278 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.444) %, meaning that it created substantial loss on money invested by shareholders. Biophytis' management efficiency ratios could be used to measure how well Biophytis manages its routine affairs as well as how well it operates its assets and liabilities.Biophytis currently holds 8.27 M in liabilities with Debt to Equity (D/E) ratio of 3.27, implying the company greatly relies on financing operations through barrowing. Biophytis has a current ratio of 1.34, which is within standard range for the sector. Note, when we think about Biophytis' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Kunz | NRX Pharmaceuticals | 59 | |
| Ming Yin | Bolt Biotherapeutics | N/A | |
| Robert MD | Protagenic Therapeutics | 73 | |
| Todd MBA | Armata Pharmaceuticals | 61 | |
| Bryan Mcmichael | Coherus BioSciences | 45 | |
| Suzanne Messere | NRX Pharmaceuticals | N/A | |
| Richard Hameister | Coherus BioSciences | N/A | |
| Dennis McBride | NRX Pharmaceuticals | N/A | |
| MPH MD | NRX Pharmaceuticals | 67 | |
| Edgar MD | Bolt Biotherapeutics | 78 | |
| Christopher Slavinsky | Coherus BioSciences | 51 | |
| James Brady | Spero Therapeutics | N/A | |
| Miles Nunn | Akari Therapeutics PLC | 55 | |
| Odile Belzunce | Innate Pharma | 44 | |
| Anne Moon | Tempest Therapeutics | N/A | |
| Mondher MD | Innate Pharma | 66 | |
| Quinn Deveraux | Inhibrx | N/A | |
| Edith MD | Bolt Biotherapeutics | 67 | |
| Satyavrat CFA | Spero Therapeutics | 51 | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| Wenyuan Shi | Armata Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -12.44 | |||
| Return On Asset | -0.53 |
Biophytis Leadership Team
Elected by the shareholders, the Biophytis' board of directors comprises two types of representatives: Biophytis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biophytis. The board's role is to monitor Biophytis' management team and ensure that shareholders' interests are well served. Biophytis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biophytis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edouard Bieth, Chief Officer | ||
| Philippe Rousseau, Chief Officer | ||
| Waly Dioh, Chief Officer | ||
| Pierre Dilda, Chief Officer | ||
| Benoit Canolle, Chief Officer | ||
| Stanislas Veillet, Chairman CEO | ||
| Rene Lafont, Scientific Board | ||
| Nicolas Fellmann, Chief Officer | ||
| FFPM MBA, Chief Officer | ||
| Teylan, Financial Controller |
Biophytis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biophytis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.44 | |||
| Return On Asset | -0.53 | |||
| Current Valuation | 9.73 B | |||
| Shares Outstanding | 286.5 K | |||
| Shares Owned By Institutions | 0.04 % | |||
| Number Of Shares Shorted | 368.95 K | |||
| Price To Book | 2.26 X | |||
| EBITDA | (15.09 M) | |||
| Net Income | (17.03 M) | |||
| Cash And Equivalents | 23.93 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Biophytis Stock
If you are still planning to invest in Biophytis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biophytis' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world |